论文部分内容阅读
1978～1989年在食管癌高发现场用复合核黄素对食管上皮重度增生患者进行阻断治疗,约2年吞(拉)网细胞学随诊一次,共6次。本文报告137例效果评价分析。第6年时与对照组比较,两组好转率分别为47.2%(42/89)及20%(7/35),进展率为19.1%(17/89)和42.9%(15/35),癌变率为1.1%(1/89)及14.3%(5/35),两组间差别均有显著性(P<0.025)。治疗组第12年好转率为46.6%(34/73),癌变率为5.5%(4/73)。12年中累计发现癌患者8例,占5.8%。远低于文献回顾调查1～12年的自然癌变率(14.9%,79/530)。
From 1978 to 1989, patients with severe hyperplasia of esophageal cancer were treated with compound riboflavin in the high-risk area of esophageal cancer. After about 2 years, swallow (pull) network cytology was followed up for 6 times. This article reports 137 cases of evaluation analysis. At the 6th year, compared with the control group, the improvement rates of the two groups were 47.2% (42/89) and 20% (7/35) respectively, and the progress rate was 19.1% (17/89) and 42.9% (15/35). The cancerous rate was 1.1% (1/89) and 14.3% (5/35). The difference between the two groups was significant (P < 0.025). In the treatment group, the rate of improvement in the 12th year was 46.6% (34/73), and the canceration rate was 5.5% (4/73). In the 12 years, 8 cases of cancer patients were found, accounting for 5.8%. Far lower than the literature review, natural carcinogenesis rates were 1 to 12 years (14.9%, 79/530).